|
Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors Clinical research trials and Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors. Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors clinical trial. Human subjects often receive the most effective healthcare possible for their Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors  Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors
Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors
For Condition: Pancreatic Islet Cell Tumor,Neuroendocrine Tumor,Carcinoid Tumor
Status: Recruiting
Sponsor(s): Pfizer ,
Synopsis: The primary objective of the study is to determine the efficacy and safety of SU-011,248 as a treatment for patients with advanced unresectable neuroendocrine tumor.
Details:
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: Eligible patient must be at least 18 years of age with a diagnosis of carcinoid or pancreatic islet cell tumor. The disease must not be amenable to surgery, radiation, or combined modality therapy with curative intent. Any side effects from prior therapy must have subsided. Blood and urine tests must show adequate bone marrow, liver, and kidney function. Exclusion Criteria: The presence of any of the following will exclude a patient from study participation: diagnosis of small-cell carcinoma, pheochromocytoma/paraganglioma, Merkel cell carcinoma, known brain or leptomeningeal disease, cardiovascular diseases or conditions, known HIV or AIDS-related illness, pregancy or breastfeeding. Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.
Total Enrollment:
Location and Contact Information:
Research Center *Recruiting*
Birmingham, Alabama, 35294
United States
Recruiting
Research Center *Recruiting*
Los Angeles, California, 90033
United States
Recruiting
Research Center *Recruiting*
Philadelphia, Pennsylvania, 19111
United States
Recruiting
Research Center *Recruiting*
Boston, Massachusetts, 02215
United States
Recruiting
Research Center *Recruiting*
San Francisco, California, 94115
United States
Recruiting
Research Center *Recruiting*
St. Louis, Missouri, 63110
United States
Recruiting
Research Center *Recruiting*
Pinckneyville, Illinois, 62274
United States
Recruiting
Research Center *Recruiting*
San Francisco, California, 94143
United States
Recruiting
Research Center *Recruiting*
Birmingham, Alabama, 35233
United States
Recruiting
Research Center *Recruiting*
Birmingham, Alabama, 35294
United States
Recruiting
Research Center *Recruiting*
Boston, Massachusetts, 02114
United States
Recruiting
Research Center *Recruiting*
Birmingham, Alabama, 35233
United States
Recruiting
Research Center *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting
Research Center *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting
Research Center *Recruiting*
Los Angeles, California, 90033
United States
Recruiting
Additional Information:
Study ID Numbers: RTKC-0511-015;
Study Start Date: March 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00056693
Other Neuroendocrine Tumor Studies:
1. Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors
Related Studies:
Other Neuroendocrine Tumor Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
Phase II Study of SU-011,248 in Patients with Neuroendocrine Tumors
|
|
|
|
|
|
|
|
